Zentalis Pharmaceuticals Future Growth

Future criteria checks 2/6

Zentalis Pharmaceuticals is forecasted to grow earnings and revenue by 12.6% and 66.9% per annum respectively. EPS is expected to grow by 19.6%. Return on equity is forecast to be -102.8% in 3 years.

Key information

12.6%

Earnings growth rate

19.6%

EPS growth rate

Biotechs earnings growth	16.9%
Revenue growth rate	66.9%
Future return on equity	-102.8%
Analyst coverage	Good
Last updated	07 Jun 2023

Recent future growth updates

Recent updates

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Mar 17

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Dec 01

Zentalis Pharmaceuticals promotes co-founder Kevin Bunker to chief scientific officer

Sep 27

Zentalis Pharmaceuticals has a new chief medical officer

Sep 19

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans

Aug 17

Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation

May 02

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Jan 12

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Oct 14

Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth

Jul 02

Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?

Mar 08

Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth

Jan 20

Zentalis initiates multiple early-stage clinical trials for cancer

Jan 06

Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?

Nov 28

Zentalis: An Interesting Small Molecule Oncology Developer For Your Watchlist

Nov 18

Earnings and Revenue Growth Forecasts

NasdaqGM:ZNTL - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	45	-303	-348	-205	10
12/31/2024	2	-294	-305	-234	10
12/31/2023	N/A	-259	-252	-215	9
3/31/2020	N/A	-53	-47	-47	N/A
12/31/2019	N/A	-46	-39	-39	N/A
12/31/2018	0	-23	-24	-24	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZNTL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ZNTL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ZNTL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ZNTL's revenue (66.9% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: ZNTL's revenue (66.9% per year) is forecast to grow faster than 20% per year.

Zentalis Pharmaceuticals Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target increased by 11% to US$51.78

Price target decreased by 12% to US$45.90

Price target decreased to US$72.50

Price target decreased to US$85.70

Price target decreased to US$90.80

Price target increased to US$97.67

Recent updates

Price target increased by 11% to US$51.78

Co-Founder notifies of intention to sell stock

High number of new directors

Zentalis Announces Presentation of Positive Phase 1B Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy

Price target decreased by 12% to US$45.90

Zentalis Pharmaceuticals, Inc. Appoints Diana Hausman to the Board of Directors

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Zentalis Pharmaceuticals, Inc. Appoints Iris Roth as Chief Operating Officer

Co-Founder notifies of intention to sell stock

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Less than half of directors are independent

Zentalis Pharmaceuticals Appoints Dr. Mark Lackner as Chief Translational Officer, Head of Biomarker Strategy

Zentalis Pharmaceuticals Appoints Dr. Mark Lackner as Chief Translational Officer, Head of Biomarker Strategy

Zentalis Pharmaceuticals, Inc. Promotes Co-Founder Kevin Bunker to Chief Scientific Officer

Zentalis Pharmaceuticals promotes co-founder Kevin Bunker to chief scientific officer

Zentalis Pharmaceuticals, Inc. Appoints Carrie Brownstein as Chief Medical Officer

Co-Founder notifies of intention to sell stock

Zentalis Pharmaceuticals has a new chief medical officer

Zentalis Pharmaceuticals, Inc Appoints Dr. Jan Skvarka to Its Board of Directors

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$72.50

Chief Operating Officer notifies of intention to sell stock

Zentalis Pharmaceuticals, Inc. Announces Resignation of Alexis M. Pinto as Chief Legal Officer and Secretary of the Company, Effective July 5, 2022

Zentalis Pharmaceuticals Promotes Cofounder Cam Gallagher to President

Zentalis Pharmaceuticals Promotes Cofounder Cam Gallagher to President

Less than half of directors are independent

Zentalis Pharmaceuticals, Inc. Announces Management Changes

Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation

Price target decreased to US$85.70

Zentalis Pharmaceuticals, Inc. Announces the Interim Data from the Ongoing Phase 1/2 Clinical Trial Evaluating Zn-c3 as a Monotherapy for the Treatment of Advanced Solid Tumors

Price target decreased to US$90.80

CFO & Treasurer notifies of intention to sell stock

Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-C3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR

Chief Operating Officer notifies of intention to sell stock

President notifies of intention to sell stock

Insider exercised options and sold US$1.3m worth of stock

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Chief Operating Officer recently sold US$781k worth of stock

Secretary & Director notifies of intention to sell stock

Price target increased to US$97.67

President notifies of intention to sell stock

Chief Legal Officer & Secretary exercised options and sold US$1.3m worth of stock

Price target increased to US$87.78

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Chief Operating Officer notifies of intention to sell stock

Chief Operating Officer notifies of intention to sell stock

Zentalis Pharmaceuticals, Inc. Announces First Patient Dosed in the Phase 1/2 Study of ZN-C3 in Combination with Gemcitabine in Patients with Osteosarcoma

President notifies of intention to sell stock

CFO & Treasurer recently bought US$500k worth of stock

Zentalis Pharmaceuticals, Inc. Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-C3 in Patients with Uterine Serous Carcinoma

Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth

Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) dropped from Russell 2500 Value Index

President notifies of intention to sell stock

President recently sold US$1.6m worth of stock

Chief Operating Officer notifies of intention to sell stock

Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?

President recently sold US$1.1m worth of stock

President notifies of intention to sell stock

Zentalis Pharmaceuticals, Inc. and Tempus Announce Strategic Collaboration to Advance Research and Development Capabilities

New 90-day low: US$36.45

Zentalis Pharmaceuticals, Inc. Appoints Enoch Kariuki as Class I Director, Member of the Audit Committee and Chairperson of the Audit Committee

Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth

Zentalis Pharmaceuticals, Inc. Announces the Initiation of Multiple Early-Stage Clinical Trials

Chief Operating Officer notifies of intention to sell stock

Zentalis initiates multiple early-stage clinical trials for cancer

New 90-day high: US$53.81

Independent Director notifies of intention to sell stock

Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?

Chief Operating Officer recently sold US$392k worth of stock